Literature DB >> 1347002

Felbamate metabolism in pediatric and adult beagle dogs.

J T Yang1, M Morris, K K Wong, N Kucharczyk, R D Sofia.   

Abstract

In a metabolism study, three male and three female pediatric dogs and three male and three female adult beagle dogs received a single oral dose of 60 mg/kg [14C]felbamate. Urine and feces were collected up to 72 hr. Excreta samples were extracted with ethyl acetate and 14C metabolite profiles were generated by HPLC analysis of the extracts. The total 14C dose recoveries were 88.2% for the pediatric and 85.9% for the adult groups; recovery in urine accounted for 61.7 and 69.7%, respectively. The 14C metabolite profiles in urine and feces were similar, with three major peaks corresponding to unchanged felbamate and two hydroxylated metabolites. There was no significant sex difference in profiles within each age group. However, the sum amount of all metabolites in the urine was higher, and the amount of unchanged drug was lower in pediatric dogs. For the 0-24 hr samples, the metabolites/drug ratio in urine was 2.0-2.1 for pediatric dogs and 1.0-1.2 for adult dogs. This indicated a higher metabolic rate in the pediatric dogs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347002

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  4 in total

Review 1.  Factors influencing the bioavailability of peroral formulations of drugs for dogs.

Authors:  S Sabnis
Journal:  Vet Res Commun       Date:  1999-11       Impact factor: 2.459

Review 2.  Felbamate in epilepsy therapy: evaluating the risks.

Authors:  J M Pellock
Journal:  Drug Saf       Date:  1999-09       Impact factor: 5.606

Review 3.  Felbamate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy.

Authors:  Katharine J Palmer; Donna McTavish
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

4.  Felbamate as an oral add-on therapy in six dogs with presumptive idiopathic epilepsy and generalized seizures resistant to drug therapy.

Authors:  Curtis Wells Dewey; Mark Rishniw; Kasie Sakovitch
Journal:  Open Vet J       Date:  2022-07-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.